File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Near-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune Therapy

TitleNear-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune Therapy
Authors
Keywordsimmunotherapy
molecular imaging
NIR-II fluorophore probe
photodynamic therapy
singlet oxygen quantum yield
Issue Date2021
Citation
ACS Nano, 2021, v. 15, n. 1, p. 515-525 How to Cite?
AbstractDevelopment of second near-infrared (NIR-II) nanoparticles (NPs) with high biocompatibility, low toxicity, and high singlet oxygen quantum yield (φΔ) to prevent tumor recurrence is highly desirable in molecular imaging and photodynamic/immune combination therapy. Here, theranostic photosensitizer BODIPY (BDP)-I-N-anti-PD-L1 NPs were developed by encapsulating the photosensitizer BDP-I-N with amphipathic poly(styrene-co-chloromethylstyrene)-graft-poly(ethylene glycol) nanocarriers through self-assembly functionalization with programmed cell death-ligand 1 (PD-L1) monoclonal antibody. These NPs exhibit highly intensive luminescence in the NIR-II window (1000-1700 nm) to real-time imaging of immune checkpoint PD-L1, high singlet oxygen quantum yield (φΔ = 73%), and an eliminating effect of primary cancers. The NPs also allow for profiling PD-L1 expression as well as accumulating in MC38 tumor and enabling molecular imaging in vivo. Upon an 808 nm laser excitation, the targeted NPs produce an emission wavelength above 1200 nm to image a tumor to a normal tissue signal ratio (T/NT) at an approximate value of 14.1. Moreover, the MC38 tumors in mice are eliminated by combining photodynamic therapy and immunotherapy within 30 days, with no tumor recurrence within a period of 40 days. In addition, the tumors do not grow in the rechallenged mice within 7 days of inoculation. Such a strategy shows a durable immune memory effect against tumor rechallenging without toxic side effects to major organs.
Persistent Identifierhttp://hdl.handle.net/10722/325511
ISSN
2023 Impact Factor: 15.8
2023 SCImago Journal Rankings: 4.593
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, Qiang-
dc.contributor.authorTian, Jiangwei-
dc.contributor.authorTian, Ye-
dc.contributor.authorSun, Qinchao-
dc.contributor.authorSun, Dan-
dc.contributor.authorWang, Feifei-
dc.contributor.authorXu, Haijun-
dc.contributor.authorYing, Guoliang-
dc.contributor.authorWang, Jigang-
dc.contributor.authorYetisen, Ali K.-
dc.contributor.authorJiang, Nan-
dc.date.accessioned2023-02-27T07:33:53Z-
dc.date.available2023-02-27T07:33:53Z-
dc.date.issued2021-
dc.identifier.citationACS Nano, 2021, v. 15, n. 1, p. 515-525-
dc.identifier.issn1936-0851-
dc.identifier.urihttp://hdl.handle.net/10722/325511-
dc.description.abstractDevelopment of second near-infrared (NIR-II) nanoparticles (NPs) with high biocompatibility, low toxicity, and high singlet oxygen quantum yield (φΔ) to prevent tumor recurrence is highly desirable in molecular imaging and photodynamic/immune combination therapy. Here, theranostic photosensitizer BODIPY (BDP)-I-N-anti-PD-L1 NPs were developed by encapsulating the photosensitizer BDP-I-N with amphipathic poly(styrene-co-chloromethylstyrene)-graft-poly(ethylene glycol) nanocarriers through self-assembly functionalization with programmed cell death-ligand 1 (PD-L1) monoclonal antibody. These NPs exhibit highly intensive luminescence in the NIR-II window (1000-1700 nm) to real-time imaging of immune checkpoint PD-L1, high singlet oxygen quantum yield (φΔ = 73%), and an eliminating effect of primary cancers. The NPs also allow for profiling PD-L1 expression as well as accumulating in MC38 tumor and enabling molecular imaging in vivo. Upon an 808 nm laser excitation, the targeted NPs produce an emission wavelength above 1200 nm to image a tumor to a normal tissue signal ratio (T/NT) at an approximate value of 14.1. Moreover, the MC38 tumors in mice are eliminated by combining photodynamic therapy and immunotherapy within 30 days, with no tumor recurrence within a period of 40 days. In addition, the tumors do not grow in the rechallenged mice within 7 days of inoculation. Such a strategy shows a durable immune memory effect against tumor rechallenging without toxic side effects to major organs.-
dc.languageeng-
dc.relation.ispartofACS Nano-
dc.subjectimmunotherapy-
dc.subjectmolecular imaging-
dc.subjectNIR-II fluorophore probe-
dc.subjectphotodynamic therapy-
dc.subjectsinglet oxygen quantum yield-
dc.titleNear-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune Therapy-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1021/acsnano.0c05317-
dc.identifier.pmid33426893-
dc.identifier.scopuseid_2-s2.0-85100053025-
dc.identifier.volume15-
dc.identifier.issue1-
dc.identifier.spage515-
dc.identifier.epage525-
dc.identifier.eissn1936-086X-
dc.identifier.isiWOS:000613942700033-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats